BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.15) by 2.61 percent. This is a 3.7 percent decrease over losses of $(1.08) per share from the same period last year.
Atlantic Equities Downgrades Moody’s to Neutral
Atlantic Equities analyst Simon Clinch downgrades Moody's (NYSE:MCO) from Overweight to Neutral.